Transitional Cell Carcinoma Terminated Phase 3 Trials for Valrubicin (DB00385)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01310803Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderTreatment